ArticleAging cell2026
Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress.
Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The genotoxic agent doxorubicin induces premature vascular aging, defined by vascular endothelial dysfunction and aortic stiffening. Excess vascular cell senescence and the accompanying senescence-associated secretory phenotype (SASP) are key mechanisms underlying doxorubicin-induced vascular dysfunction, in part, by promoting excess mitochondrial oxidative stress, which reduces the bioavailability of the vasodilatory molecule nitric oxide (NO). In the present study, we assessed if the natural senolytic fisetin mitigates doxorubicin-induced cellular senescence and the SASP to improve vascular function following doxorubicin administration and explored the underlying mechanisms. Young adult (6 months) mice were treated with doxorubicin, followed by oral, intermittent fisetin supplementation (100 mg/kg/day; 1 week on treatment-2 weeks off treatment-1 week on treatment). Vascular endothelial function, aortic stiffness, cellular senescence markers, SASP expression, NO bioavailability, and mitochondrial oxidative stress were assessed. Parallel experiments in human aortic endothelial cells were conducted to provide further mechanistic insight. Fisetin mitigated excess vascular cell senescence and the SASP in young mice administered doxorubicin and reversed doxorubicin-induced endothelial dysfunction (p < 0.001) and aortic stiffening (p < 0.001), in part through suppression of excess cellular senescence, higher NO bioavailability, and lower mitochondrial oxidative stress. Modulation of the circulating SASP (plasma) also contributed to the observed vascular improvements with fisetin. In vitro, fisetin reduced cellular senescence in doxorubicin-exposed endothelial cells, supporting isolated artery and in vivo observations. These findings identify oral intermittent fisetin supplementation as a promising therapeutic strategy for targeting excess cellular senescence to improve vascular function in settings of premature vascular aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.